Novel aspects of vitamin C: how important is glypican-1 recycling?

Trends in Molecular Medicine

Volumn 13, Issue 4, 2007, Pages 143-149

  Fransson, Lars Åke ^a   Mani, Katrin ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; COPPER; GLYPICAN 1; HYPOXIA INDUCIBLE FACTOR 1; NITRIC OXIDE SYNTHASE; POLYAMINE; PROTEOHEPARAN SULFATE;

ARTICLE; CELL GROWTH; GENETIC TRANSCRIPTION; HOST RESISTANCE; HUMAN; INFECTION RESISTANCE; MAMMAL CELL; PROTEIN FOLDING; SCURVY; VITAMIN INTAKE;

ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; GLYPICANS; HUMANS; MODELS, BIOLOGICAL; NITRIC OXIDE; NUTRITIONAL REQUIREMENTS; OXYGEN;

MAMMALIA;

EID: 34047097248     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.02.005     Document Type: Article

References (59)

1. Prockop D.J., and Kivirikko K.I. Collagens, molecular biology, diseases and potentials for therapy. Annu. Rev. Biochem. 64 (1995) 403-434
2. De Tullio M.C., and Arrigoni O. Hopes, disillusions and more hopes from vitamin C. CMLS. Cell. Mol. Life Sci. 61 (2005) 209-219
3. Duarte T.L., and Lunec J. When is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin C. Free Radic. Res. 39 (2005) 671-686
4. Smirnoff N. l-ascorbic acid biosynthesis. Vitam. Horm. 61 (2002) 241-266
5. Levine M., et al. A new recommended dietary allowance of vitamin C for healthy young women. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9842-9846
6. Maeda N., et al. Aortic wall damage in mice unable to synthesize ascorbic acid. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 841-846
7. Willis G.C. An experimental study of the intimal ground substance in atherosclerosis. Can. Med. Assoc. J. 69 (1953) 17-22
8. Willis G.C. The reversibility of atherosclerosis. Can. Med. Assoc. J. 77 (1957) 106-108
9. Sotiriou S., et al. Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat. Med. 8 (2002) 514-517
10. Agus D.B., et al. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J. Clin. Invest. 100 (1997) 2842-2848
11. Rumsey S.C., et al. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J. Biol. Chem. 272 (1997) 18982-18989
12. Rumsey S.C., et al. Dehydroascorbic acid transport by GLUT4 in Xenopus oocytes and isolated rat adipocytes. J. Biol. Chem. 275 (2000) 28246-28253
13. Wilson J.X. Regulation of vitamin C transport. Annu. Rev. Nutr. 25 (2005) 105-125
14. +-dependent, electroneural l-ascorbate transport across brush border membrane vesicles from human small intestine: Inhibition by d-erythorbate. FEBS Lett. 108 (1979) 473-476
15. Bianchi J., et al. Dehydroascorbic acid and ascorbic acid transport systems in the guinea pig ileum. Am. J. Physiol. 250 (1986) 461-468
16. Stolze I.P., et al. Regulation of HIF:prolyl hydroxylases. Novartis Found. Symp. 272 (2006) 15-36
17. May J.M. How does ascorbic acid prevent endothelial dysfunction?. Free Radic. Biol. Med. 28 (2000) 1421-1429
18. Huang A., et al. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J. Biol. Chem. 275 (2000) 17399-17406
19. Heller R., et al. l-Ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydropbiopterin. J. Biol. Chem. 276 (2001) 40-47
20. Kim H.J., et al. Ascorbic acid synthesis due to l-gulono-1,4-lactone oxidase expression enhances NO production in endothelial cells. Biochem. Biophys. Res. Commun. 345 (2006) 1657-1662
21. Kim J.Y., and Lee S.M. Effect of ascorbic acid on hepatic vasoregulatory gene expression during polymicrobial sepsis. Life Sci. 75 (2004) 2015-2026
22. Korcok J., et al. Sepsis inhibits reduction of dehydroascorbic acid and accumulation of ascorbate in astroglial cultures: intracellular ascorbate depletion increases nitric oxide synthase induction and glutamate uptake inhibition. J. Neurochem. 81 (2002) 185-193
23. Wu F., et al. Ascorbate inhibits iNOS expression in endotoxin- and IFNγ- stimulated rat skeletal muscle endothelial cells. FEBS Lett. 520 (2002) 122-126
24. Lei S.Z., et al. Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron 8 (1992) 1087-1099
25. Jaffrey S.R., et al. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat. Cell Biol. 3 (2001) 193-197
26. Jaffrey S.R., et al. Nitrosopeptide mapping: a novel methodology reveals S-nitrosylation of dexras1 on a single cysteine residue. Chem. Biol. 9 (2002) 1329-1335
27. Foster M.W., et al. S-nitrosylation in health and disease. Trends Mol. Med. 9 (2003) 160-168
28. Hess D.T., et al. Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell Biol. 6 (2005) 150-166
29. Greco T.M., et al. Identification of S-nitrosylation motifs by site-specific mapping of the S-nitrosocysteine proteome in human vascular smooth muscle cells. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7420-7425
30. Field C.J., et al. Nutrients and their role in host resistance to infection. J. Leukoc. Biol. 71 (2002) 16-32
31. Reynaert N.L., et al. Nitric oxide represses inhibitory κB kinase through S-nitrosylation. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 88945-88950
32. Sumbayev V.V., et al. HIF-1 α protein as a target for S-nitrosation. FEBS Lett. 535 (2003) 106-112
33. Knowles H.J., et al. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 63 (2003) 1764-1768
34. Fransson L.-A., et al. Novel aspects of glypican glycobiology. Cell. Mol. Life Sci. 61 (2004) 1016-1024
35. Cheng F., et al. Nitric oxide-dependent processing of heparan sulfate in recycling S-nitrosylated glypican-1 takes place in caveolin-1-containing endosomes. J. Biol. Chem. 277 (2002) 44431-44439
36. Mani K., et al. Prion, amyloid β-derived Cu(II) ions, or free Zn(II) ions support S-nitroso-dependent autocleavage of glypican-1 heparan sulfate. J. Biol. Chem. 278 (2003) 38956-38965
37. Mani K., et al. Involvement of glycosylphosphatidylinositol-linked ceruloplasmin in the copper/zinc-nitric oxide-dependent degradation of glypican-1 heparan sulfate in rat C6 glioma cells. J. Biol. Chem. 279 (2004) 12918-12923
38. Cappai R., et al. The amyloid precursor protein (APP) of Alzheimer disease and its paralog, APLP2, modulate the Cu/Zn-nitric oxide-catalyzed degradation of glypican-1 heparan sulfate in vivo. J. Biol. Chem. 280 (2005) 13913-13920
39. Cheng F., et al. Copper-dependent co-internalization of the prion protein and glypican-1. J. Neurochem. 98 (2006) 1445-1457
40. Smith J.N., and Dasgupta T.P. Kinetics and mechanism of the decomposition of S-nitrosoglutathione by l-ascorbic acid and copper ions in aqueous solution to produce nitric oxide. Nitric Oxide 4 (2000) 57-66
41. Ding K., et al. Modulations of glypican-1 heparan sulfate structure by inhibition of endogenous polyamine synthesis. Mapping of spermine-binding sites and heparanase, heparin lyase and nitrix oxide/nitrite cleavage sites. J. Biol. Chem. 276 (2001) 46779-46791
42. Ding K., et al. Copper-dependent autocleavage of glypican-1 heparan sulfate by nitric oxide derived from intrinsic nitrosothiols. J. Biol. Chem. 277 (2002) 33353-33360
43. Mani K., et al. Defective nitric oxide-dependent, deaminative cleavage of glypican-1 heparan sulfate in Niemann-Pick C1 fibroblasts. Glycobiology 16 (2006) 711-718
44. Belting M., et al. Glypican-1 is a vehicle for polyamine uptake in mammalian cells. A pivotal role for nitrosothiol-derived nitric oxide. J. Biol. Chem. 278 (2003) 47181-47189
45. Sandgren S., et al. Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. J. Biol. Chem. 277 (2002) 38877-38883
46. Belting M., et al. Nuclear delivery of macromolecules: barriers and carriers. Adv. Drug Deliv. Rev. 57 (2005) 505-527
47. Martin A. Antioxidants vitamin E and C and risk of Alzheimer's disease. Nutr. Rev. 61 (2003) 69-73
48. Levine G.N., et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 93 (1996) 1107-1113
49. Schindler T.H., et al. Coronary vasoregulation in patients with various risk factors in response to cold pressor testing: contrasting myocardial blood flow responses to short- and long-term vitamin C administration. J. Am. Coll. Cardiol. 42 (2003) 814-822
50. Huang J., et al. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11720-11724
51. Passage E., et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat. Med. 10 (2004) 396-401
52. Eldridge C.F., et al. Differentiation of axon-related Schwann cells in vitro. I. Ascorbic acid regulates basal lamina assembly and myelin formation. J. Cell Biol. 105 (1987) 1023-1034
53. Chen Q., et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13604-13609
54. Fornai F., et al. Subcellular localization of a glutathione-dependent dehydroascorbic acid reductase within specific rat brain regions. Neuroscience 104 (2001) 15-31
55. Del Bello B., et al. Purification of NADPH-dependent dehydroascorbic acid reductase from rat liver and its identification with 3α-hydroxysteroid dehydrogenase. Biochem. J. 304 (1994) 385-390
56. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J. Clin. Invest. 78 (1986) 1-5
57. Mani K., et al. Constitutive and vitamin C-induced, NO-catalyzed release of heparan sulfate from recycling glypican-1 in late endosomes. Glycobiology 12 (2006) 1251-1261
58. Fivaz M., et al. Differential sorting and fate of endocytosed GPI-anchored proteins. EMBO J. 21 (2002) 3989-4000
59. Horton D., and Philips K.D. The nitrous acid deamination of glycosides and acetates of 2-amino-2-deoxy-d-glucose. Carbohydr. Res. 30 (1973) 367-374